Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2013

Open Access 01-12-2013 | Research

A mathematical model of the impact of present and future malaria vaccines

Authors: Edward A Wenger, Philip A Eckhoff

Published in: Malaria Journal | Issue 1/2013

Login to get access

Abstract

Background

With the encouraging advent of new malaria vaccine candidates, mathematical modelling of expected impacts of present and future vaccines as part of multi-intervention strategies is especially relevant.

Methods

The impact of potential malaria vaccines is presented utilizing the EMOD model, a comprehensive model of the vector life cycle coupled to a detailed mechanistic representation of intra-host parasite and immune dynamics. Values of baseline transmission and vector feeding behaviour parameters are identified, for which local elimination is enabled by layering pre-erythrocytic vaccines of various efficacies on top of high and sustained insecticide-treated net coverage. The expected reduction in clinical cases is further explored in a scenario that targets children by adding a pre-erythrocytic vaccine to the EPI programme for newborns.

Results

At high transmission, there is a minimal reduction in clinical disease cases, as the time to infection is only slightly delayed. At lower transmission, there is an accelerating community-level protection that has subtle dependences on heterogeneities in vector behaviour, ecology, and intervention coverage. At very low transmission, the trend reverses as many children are vaccinated to prevent few cases.

Conclusions

The maximum-impact setting is one in which the impact of increasing bed net coverage has saturated, vector feeding is primarily outdoors, and transmission is just above the threshold where small perturbations from a vaccine intervention result in large community benefits.
Appendix
Available only for authorised users
Literature
1.
2.
Akachi Y, Atun R: Effect of investment in malaria control on child mortality in sub-Saharan Africa in 2002–2008. PLoS ONE. 2011, 6: e21309-10.1371/journal.pone.0021309.PubMedCentralCrossRefPubMed
3.
Lim SS, Fullman N, Stokes A, Ravishankar N, Masiye F, Murray CJL, Gakidou E: Net benefits: a multicountry analysis of observational data examining associations between insecticide-treated mosquito nets and health outcomes. PLoS Med. 2011, 8: e1001091-10.1371/journal.pmed.1001091.PubMedCentralCrossRefPubMed
4.
Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI: The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005, 434: 214-217. 10.1038/nature03342.PubMedCentralCrossRefPubMed
5.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-467. 10.1056/NEJMoa0808859.PubMedCentralCrossRefPubMed
6.
Trape JF: The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001, 64 (1 Suppl): 12-17.PubMed
7.
Hemingway J, Ranson H: Insecticide resistance in insect vectors of human disease. Annu Rev Entomol. 2000, 45: 371-391. 10.1146/annurev.ento.45.1.371.CrossRefPubMed
8.
Russell TL, Govella NJ, Azizi S, Drakeley CJ, Kachur SP, Killeen GF: Increased proportions of outdoor feeding among residual malaria vector populations following increased use of insecticide-treated nets in rural Tanzania. Malar J. 2011, 10: 80-10.1186/1475-2875-10-80.PubMedCentralCrossRefPubMed
9.
Gillies MT, Smith A: The effect of a residual house-spraying campaign in East Africa on species balance in the Anopheles funestus group. The replacement of A. funestus Giles by A. rivulorum Leeson. Bull Entomol Res. 1960, 51: 243-10.1017/S0007485300057953.CrossRef
10.
Holder AA, Guevara Patiño JA, Uthaipibull C, Syed SE, Ling IT, Scott-Finnigan T, Blackman MJ: Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia. 1999, 41: 409-414.PubMed
11.
Horrocks P, Kyes SA, Bull PC, Deitsch KW: Molecular aspects of antigenic variation in Plasmodium falciparum. Molecular Approaches to Malaria. Edited by: Sherman IW. 2005, Washington: ASM Press, 399-415.
12.
Recker M, Buckee CO, Serazin A, Kyes S, Pinches R, Christodoulou Z, Springer AL, Gupta S, Newbold CI: Antigenic variation in Plasmodium falciparum malaria involves a highly structured switching pattern. PLoS Pathog. 2011, 7: e1001306-10.1371/journal.ppat.1001306.PubMedCentralCrossRefPubMed
13.
Nussenzweig RS, Vanderberg J, Most H, Orton C: Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature. 1967, 216: 160-162. 10.1038/216160a0.CrossRefPubMed
14.
Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WHH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KPWJ, Tornieporth N, Cohen JD, Doherty T: Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001, 358: 1927-1934. 10.1016/S0140-6736(01)06957-4.CrossRefPubMed
15.
Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitié MA, Dubovsky F, Menéndez C, Tornieporth N, Ballou WR, Thompson R, Cohen J: Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004, 364: 1411-1420. 10.1016/S0140-6736(04)17223-1.CrossRefPubMed
16.
Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menéndez C, Dubovsky F, Cohen J, Thompson R, Ballou WR: Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet. 2005, 366: 2012-2018. 10.1016/S0140-6736(05)67669-6.CrossRefPubMed
17.
Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitié MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein: Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008, 359: 2521-2532. 10.1056/NEJMoa0807381.PubMedCentralCrossRefPubMed
18.
The RTS,S Clinical Trials Partnership: First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011, 365: 1863-1875.CrossRef
19.
Ballou WR: The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 2009, 31: 492-500. 10.1111/j.1365-3024.2009.01143.x.CrossRefPubMed
20.
White MT, Griffin JT, Drakeley CJ, Ghani AC: Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar J. 2010, 9: 82-10.1186/1475-2875-9-82.PubMedCentralCrossRefPubMed
21.
Maire N, Aponte JJ, Ross A, Thompson R, Alonso P, Utzinger J, Tanner M, Smith T: Modeling a field trial of the RTS,S/AS02A malaria vaccine. Am J Trop Med Hyg. 2006, 75 (2 Suppl): 104-110.PubMed
22.
Moorthy VS, Ballou WR: Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J. 2009, 8: 312-10.1186/1475-2875-8-312.PubMedCentralCrossRefPubMed
23.
Matuschewski K, Mueller AK: Vaccines against malaria - an update. FEBS Journal. 2007, 274: 4680-4687. 10.1111/j.1742-4658.2007.05998.x.CrossRefPubMed
24.
Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A: Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005, 23: 3131-3138. 10.1016/j.vaccine.2004.12.019.CrossRefPubMed
25.
Miyata T, Harakuni T, Tsuboi T, Sattabongkot J, Kohama H, Tachibana M, Matsuzaki G, Torii M, Arakawa T: Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect Immun. 2010, 78: 3773-3782. 10.1128/IAI.00306-10.PubMedCentralCrossRefPubMed
26.
Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP: Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with Montanide ISA 51. PLoS ONE. 2008, 3: e2636-10.1371/journal.pone.0002636.PubMedCentralCrossRefPubMed
27.
Ross R: The Prevention of Malaria. New York: , E.P. Dutton & Co.; 1910
28.
29.
Molineaux L, Gramiccia G: The Garki Project: research on the epidemiology and control of malaria in the Sudan savanna of West Africa. World Health Organ, Geneva. 1980
30.
Struchiner CJ, Halloran ME, Spielman A: Modeling malaria vaccines I: new uses for old ideas. Math Biosci. 1989, 94: 87-113. 10.1016/0025-5564(89)90073-4.CrossRefPubMed
31.
Smith T, Killeen G, Maire N, Ross A, Molineaux L, Tediosi F, Hutton G, Utzinger J, Dietz K, Tanner M: Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: overview. Am J Trop Med Hyg. 2006, 75 (2 Suppl): 1-10.PubMed
32.
McKenzie FE, Baird JK, Beier JC, Lal AA, Bossert WH: A biologic basis for integrated malaria control. Am J Trop Med Hyg. 2002, 67: 571-577.PubMedCentralPubMed
33.
Smith DL, McKenzie FE, Snow RW, Hay SI: Revisiting the basic reproductive number for malaria and its implications for malaria control. PLoS Biol. 2007, 5: e42-10.1371/journal.pbio.0050042.PubMedCentralCrossRefPubMed
34.
Penny MA, Maire N, Studer A, Schapira A, Smith TA: What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE. 2008, 3: e3193-10.1371/journal.pone.0003193.PubMedCentralCrossRefPubMed
35.
Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, Bousema T, Drakeley CJ, Ferguson NM, Basáñez MG, Ghani AC: Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010, 7: e1000324-10.1371/journal.pmed.1000324.PubMedCentralCrossRefPubMed
36.
Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, Brooks A, Penny M, Tanner M: Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med. 2012, 9: e1001157-10.1371/journal.pmed.1001157.PubMedCentralCrossRefPubMed
37.
38.
Eckhoff P: P. falciparum infection durations and infectiousness are shaped by antigenic variation and innate and adaptive host immunity in a mathematical model. PLoS ONE. 2012, 7: e44950-10.1371/journal.pone.0044950.PubMedCentralCrossRefPubMed
39.
Eckhoff P: Mathematical models of within-host and transmission dynamics to determine effects of malaria interventions in a variety of transmission settings. Am J Trop Med Hyg. 2013, 88: 817-827. 10.4269/ajtmh.12-0007.PubMedCentralCrossRefPubMed
40.
Kiszewski A, Mellinger A, Spielman A, Malaney P, Sachs SE, Sachs J: A global index representing the stability of malaria transmission. Am J Trop Med Hyg. 2004, 70: 486-498.PubMed
41.
Craig MH, Snow RW, le Sueur D: A climate-based distribution model of malaria transmission in sub-Saharan Africa. Parasitol Today. 1999, 15: 105-111. 10.1016/S0169-4758(99)01396-4.CrossRefPubMed
42.
Eckhoff PA: Malaria parasite diversity and transmission intensity affect development of parasitological immunity in a mathematical model. Malar J. 2012, 11: 419-10.1186/1475-2875-11-419.PubMedCentralCrossRefPubMed
43.
Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L: A model for natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic areas. Am J Trop Med Hyg. 2006, 75 (2 Suppl): 19-31.PubMed
44.
Sinden RE, Butcher GA, Billker O, Fleck SL: Regulation of infectivity of Plasmodium to the mosquito vector. Adv Parasitol. 1996, 38: 53-117.CrossRefPubMed
45.
Smalley ME, Sinden RE: Plasmodium falciparum gametocytes: their longevity and infectivity. Parasitology. 1977, 74: 1-8. 10.1017/S0031182000047478.CrossRefPubMed
46.
Jeffery GM, Eyles DE: Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection. Am J Trop Med Hyg. 1955, 4: 781-789.PubMed
47.
Schneider P, Bousema JT, Gouagna LC, Otieno S, van de Vegte-Bolmer M, Omar SA, Sauerwein RW: Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg. 2007, 76: 470-474.PubMed
48.
Naotunne TS, Karunaweera ND, Del Giudice G: Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential. J Exp Med. 1991, 173: 523-529. 10.1084/jem.173.3.523.CrossRefPubMed
49.
Naotunne TS, Karunaweera ND, Mendis KN, Carter R: Cytokine-mediated inactivation of malarial gametocytes is dependent on the presence of white blood cells and involves reactive nitrogen intermediates. Immunology. 1993, 78: 555-562.PubMedCentralPubMed
50.
Smith DL, Dushoff J, Snow RW, Hay SI: The entomological inoculation rate and Plasmodium falciparum infection in African children. Nature. 2005, 438: 492-495. 10.1038/nature04024.PubMedCentralCrossRefPubMed
51.
Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P, Meuwissen J, Lyimo E, Takken W, Teuscher T, Tanner M: Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmission. Acta Trop. 1993, 54: 55-72. 10.1016/0001-706X(93)90068-M.CrossRefPubMed
52.
53.
Beier JC, Killeen GF, Githure JI: Short report: entomologic inoculation rates and Plasmodium falciparum malaria prevalence in Africa. Am J Trop Med Hyg. 1999, 61: 109-113.PubMed
54.
55.
Killeen GF, Smith TA, Ferguson HM, Mshinda H, Abdulla S, Lengeler C, Kachur SP: Preventing childhood malaria in Africa by protecting adults from mosquitoes with insecticide-treated nets. PLoS Med. 2007, 4: e229-10.1371/journal.pmed.0040229.PubMedCentralCrossRefPubMed
56.
Magesa SM, Wilkes TJ, Mnzava AE, Njunwa KJ, Myamba J, Kivuyo MD, Hill N, Lines JD, Curtis CF: Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic for malaria. Part 2. Effects on the malaria vector population. Acta Trop. 1991, 49: 97-108. 10.1016/0001-706X(91)90057-Q.CrossRefPubMed
57.
Robert V, Carnevale P: Influence of deltamethrin treatment of bed nets on malaria transmission in the Kou valley, Burkina Faso. Bull World Health Organ. 1991, 69: 735-740.PubMedCentralPubMed
58.
Atieli HE, Zhou G, Afrane Y, Lee MC, Mwanzo I, Githeko AK, Yan G: Insecticide-treated net (ITN) ownership, usage, and malaria transmission in the highlands of western Kenya. Parasit Vectors. 2011, 4: 113-10.1186/1756-3305-4-113.PubMedCentralCrossRefPubMed
59.
Macintyre K, Littrell M, Keating J, Hamainza B, Miller J, Eisele TP: Determinants of hanging and use of ITNs in the context of near universal coverage in Zambia. Health Policy Plan. 2012, 27: 316-325. 10.1093/heapol/czr042.CrossRefPubMed
60.
Eisele TP, Keating J, Littrell M, Larsen D, Macintyre K: Assessment of insecticide-treated bednet use among children and pregnant women across 15 countries using standardized national surveys. Am J Trop Med Hyg. 2009, 80: 209-214.PubMed
61.
Seyoum A, Sikaala CH, Chanda J, Chinula D, Ntamatungiro AJ, Hawela M, Miller JM, Russell TL, Briët OJT, Killeen GF: Human exposure to anopheline mosquitoes occurs primarily indoors, even for users of insecticide-treated nets in Luangwa Valley, South-east Zambia. Parasit Vectors. 2012, 5: 101-10.1186/1756-3305-5-101.PubMedCentralCrossRefPubMed
62.
Huho B, Briët O, Seyoum A, Sikaala C, Bayoh N, Gimnig J, Okumu F, Diallo D, Abdulla S, Smith TA, Killeen GF: Consistently high estimates for the proportion of human exposure to malaria vector populations occurring indoors in rural Africa. Int J Epidemiol. 2013, 42: 235-247. 10.1093/ije/dys214.PubMedCentralCrossRefPubMed
63.
O’Meara WP, Smith N, Ekal E, Cole D, Ndege S: Spatial distribution of bednet coverage under routine distribution through the public health sector in a rural district in Kenya. PLoS ONE. 2011, 6: e25949-10.1371/journal.pone.0025949.CrossRefPubMed
64.
Le Menach A, Tatem AJ, Cohen JM, Hay SI, Randell H, Patil AP, Smith DL: Travel risk, malaria importation and malaria transmission in Zanzibar. Sci Rep. 2011, 1: 93-PubMedCentralCrossRefPubMed
65.
Wesolowski A, Eagle N, Tatem AJ, Smith DL, Noor AM, Snow RW, Buckee CO: Quantifying the impact of human mobility on malaria. Science. 2012, 338: 267-70. 10.1126/science.1223467.PubMedCentralCrossRefPubMed
66.
Snow RW, Craig M, Deichmann U, Marsh K: Estimating mortality, morbidity and disability due to malaria among Africa’s non-pregnant population. Bull World Health Organ. 1999, 77: 624-640.PubMedCentralPubMed
67.
Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K: Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med. 1998, 4: 358-360. 10.1038/nm0398-358.PubMedCentralCrossRefPubMed
68.
Drakeley C, Sutherland C, Bousema JT, Sauerwein RW, Targett GAT: The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends Parasitol. 2006, 22: 424-430. 10.1016/j.pt.2006.07.001.CrossRefPubMed
69.
Bejon P, Williams TN, Liljander A, Noor AM, Wambua J, Ogada E, Olotu A, Osier FHA, Hay SI, Färnert A, Marsh K: Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med. 2010, 7: e1000304-10.1371/journal.pmed.1000304.PubMedCentralCrossRefPubMed
70.
Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R: Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012, 9: e1001165-10.1371/journal.pmed.1001165.PubMedCentralCrossRefPubMed
71.
Tediosi F, Maire N, Penny M, Studer A, Smith TA: Simulation of the cost-effectiveness of malaria vaccines. Malar J. 2009, 8: 127-10.1186/1475-2875-8-127.PubMedCentralCrossRefPubMed
72.
Bejon P, White MT, Olotu A, Bojang K, Lusingu JPA, Salim N, Otsyula NN, Agnandji ST, Asante KP, Owusu-Agyei S, Abdulla S, Ghani AC: Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis. 2013, 13: 319-327. 10.1016/S1473-3099(13)70005-7.PubMedCentralCrossRefPubMed
73.
Feachem RGA, Phillips AA, Targett GA: Shrinking the Malaria Map: a Prospectus on Malaria Elimination. 2009, San Francisco: The Global Health Group: UCSF Global Health Sciences
74.
Larsen DA, Keating J, Miller J, Bennett A, Changufu C, Katebe C, Eisele TP: Barriers to insecticide-treated mosquito net possession 2 Years after a mass free distribution campaign in Luangwa District, Zambia. PLoS ONE. 2010, 5: e13129-10.1371/journal.pone.0013129.PubMedCentralCrossRefPubMed
75.
Grabowsky M, Nobiya T, Selanikio J: Sustained high coverage of insecticide-treated bednets through combined Catch-up and Keep-up strategies. Trop Med Int Health. 2007, 12: 815-822. 10.1111/j.1365-3156.2007.01862.x.CrossRefPubMed
76.
Van Den Berg H, Takken W: Viewpoint: a framework for decision-making in integrated vector management to prevent disease. Trop Med Int Health. 2007, 12: 1230-1238. 10.1111/j.1365-3156.2007.01905.x.CrossRefPubMed
77.
Killeen GF, McKenzie FE, Foy BD, Schieffelin C, Billingsley PF, Beier JC: The potential impact of integrated malaria transmission control on entomologic inoculation rate in highly endemic areas. Am J Trop Med Hyg. 2000, 62: 545-551.PubMedCentralPubMed
78.
Caldas de Castro M, Yamagata Y, Mtasiwa D, Tanner M, Utzinger J, Keiser J, Singer BH: Integrated urban malaria control: a case study in Dar es Salaam, Tanzania. Am J Trop Med Hyg. 2004, 71 (2 Suppl): 103-117.PubMed
Metadata
Title
A mathematical model of the impact of present and future malaria vaccines
Authors
Edward A Wenger
Philip A Eckhoff
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2013
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-12-126

Other articles of this Issue 1/2013

Malaria Journal 1/2013 Go to the issue

Research

Molecular epidemiology of Plasmodium vivax in Latin America: polymorphism and evolutionary relationships of the circumsporozoite gene

Research

Plasmodium vivax malaria incidence over time and its association with temperature and rainfall in four counties of Yunnan Province, China

Research

Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia

Research

Universal coverage with insecticide-treated nets – applying the revised indicators for ownership and use to the Nigeria 2010 malaria indicator survey data

Research

Malaria relevance and diagnosis in febrile Burkina Faso travellers: a prospective study

Case study

Malaria control in South Sudan, 2006–2013: strategies, progress and challenges
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits